TRASTUZUMAB AND PERTUZUMAB COMBINATION THERAPY ACTIVATES COMPLEMENT-DEPENDENT CYTOTOXICITY AND PHAGOCYTOSIS AGAINST HER2+BREAST CANCER

被引：0
|
作者：
Tsao, Li-Chung [1 ]
Hartman, Zachary [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617
引用
收藏
页码：A647 / A647
页数：1
相关论文
共 50 条
  • [31] Complete disappearance of ER+/HER2+breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition
    Arpino, G
    Weiss, H
    Wakeling, AE
    Osborne, K
    Schiff, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S15 - S15
  • [32] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [33] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
  • [34] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [35] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [36] Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer
    Takada, Koji
    Kashiwagi, Shinichiro
    Goto, Wataru
    Asano, Yuka
    Morisaki, Tamami
    Fujita, Hisakazu
    Takashima, Tsutomu
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2018, 38 (04) : 2285 - 2294
  • [37] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [38] Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Stephanie Gu
    Stephen Dusza
    Elizabeth Quigley
    Helen Haliasos
    Alina Markova
    Michael Marchetti
    Andrea P. Moy
    Chau Dang
    Shanu Modi
    Diana Lake
    Sarah Noor
    Mario E. Lacouture
    Breast Cancer Research and Treatment, 2024, 203 : 271 - 280
  • [39] Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models
    Veeraraghavan, J.
    Sethunath, V.
    Qin, L.
    Shea, M. J.
    Mitchell, T.
    De Angelis, C.
    Nanda, S.
    Diala, I.
    Lalani, A. S.
    Hilsenbeck, S. G.
    Rimawi, M. F.
    Osborne, C. K.
    Schiff, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [40] The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    Shea, Martin J.
    Mitchell, Tamika
    Pereira, Resel
    Qin, Lanfang
    Nanda, Sarmistha
    De Angelis, Carmine
    Goutsouliak, Kristina
    Diala, Irmina
    Lalani, Alshad S.
    Mehravaran, Sepideh
    Hilsenbeck, Susan G.
    Nagi, Chandandeep
    Gutierrez, Carolina
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2019, 79 (13)
12345